We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.1B
AUM Growth
+$208M
Cap. Flow
+$30.3M
Cap. Flow %
2.77%
Top 10 Hldgs %
54.38%
Holding
136
New
36
Increased
27
Reduced
26
Closed
32

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$35.5M
2
NVO
Novo Nordisk
NVO
+$19.7M
3
URGN icon
UroGen Pharma
URGN
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.4M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$10.9M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$19.7M
2
CELG
Celgene Corp
CELG
+$18.8M
3
ITRN icon
Ituran Location and Control
ITRN
+$14.6M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.6M
5
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 56.49%
2 Miscellaneous 34.04%
3 Technology 6.57%
4 Consumer Discretionary 1.18%
5 Industrials 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGIC
101
DELISTED
Magic Software Enterprises
MGIC
$324K 0.03%
+38,784
New +$323K
BNTC icon
102
Benitec Biopharma
BNTC
$396M
$228K 0.02%
471
– –
CLRB icon
103
Cellectar Biosciences
CLRB
$22.7M
$206K 0.02%
292
– –
ABEO icon
104
Abeona Therapeutics
ABEO
$320M
– –
-10,801
Closed -$1.93M
ACIU icon
105
AC Immune
ACIU
$266M
– –
-310,613
Closed -$2.94M
ADVM
106
DELISTED
Adverum Biotechnologies
ADVM
– –
-6,336
Closed -$200K
AGIO icon
107
Agios Pharmaceuticals
AGIO
$2.01B
– –
-67,500
Closed -$3.11M
ALLO icon
108
Allogene Therapeutics
ALLO
$598M
– –
-113,437
Closed -$3.06M
APLS
109
DELISTED
Apellis Pharmaceuticals
APLS
– –
-117,000
Closed -$1.54M
CLSD
110
DELISTED
Clearside Biomedical
CLSD
– –
-79,008
Closed -$1.27M
EVOK
111
DELISTED
Evoke Pharma
EVOK
– –
-9,798
Closed -$3.5M
ITRN icon
112
Ituran Location and Control
ITRN
$1.04B
– –
-122,177
Closed -$14.6M
KZR
113
DELISTED
Kezar Life Sciences
KZR
– –
-2,000
Closed -$472K
LRMR icon
114
Larimar Therapeutics
LRMR
$395M
– –
-31,667
Closed -$1.88M
SAGE
115
DELISTED
Sage Therapeutics
SAGE
– –
-103,500
Closed -$9.91M
SAGE
116
PUT
DELISTED
Sage Therapeutics
SAGE
– –
-24,500
Closed -$2.35M
SGMO
117
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-340,000
Closed -$3.9M
SRRK icon
118
Scholar Rock
SRRK
$5.97B
– –
-175,511
Closed -$4.03M
SVRA icon
119
Savara
SVRA
$1.11B
– –
-110,000
Closed -$833K
VKTX icon
120
Viking Therapeutics
VKTX
$3.42B
– –
-745,727
Closed -$5.71M
VRCA icon
121
Verrica Pharmaceuticals
VRCA
$79.9M
– –
-9,700
Closed -$791K
XBI icon
122
State Street SPDR S&P Biotech ETF
XBI
$10.7B
– –
-45,000
Closed -$3.83M
PVLA
123
Palvella Therapeutics
PVLA
$2.22B
– –
-8,750
Closed -$1.86M
WHWK
124
Whitehawk Therapeutics
WHWK
$233M
– –
-75,455
Closed -$1.92M
ACGN
125
DELISTED
Aceragen Inc
ACGN
– –
-26,236
Closed -$1.23M
2 3 4
5
6

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q1 2019 Portfolio in Review

As of Q1 2019, Sphera Funds Management held 136 positions worth $1.1B, up 23% from $887M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sphera Funds Management's Q1 2019 filing shows 36 new, 27 increased, 26 reduced and 32 closed positions. Its largest new stake was Johnson & Johnson: 265,000 shares worth $37M. The largest sale was Viatris, an estimated $19.7M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 62% a quarter earlier, followed by Miscellaneous and Technology.

  • Sphera Funds Management's largest Q1 2019 buy was Johnson & Johnson: 265,000 shares worth $37M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q1 2019, an estimated $12.4M increase.
  • Sphera Funds Management's biggest Q1 2019 reduction was Viatris, cutting an estimated $19.7M.
  • Sphera Funds Management fully exited Ituran Location and Control in Q1 2019, selling an estimated $14.6M.
  • Sphera Funds Management's ten largest holdings make up 54% of its $1.1B portfolio in Q1 2019.
  • Sphera Funds Management opened 36 new positions and closed 32 in Q1 2019.
  • Sphera Funds Management's portfolio value rose 23% quarter-over-quarter to $1.1B.

Based on Sphera Funds Management's 13F filing for Q1 2019, filed 15 May 2019.